Remophos 667mg Tablet | 1 Strip

✔️ Dosage & Administration

Adults (Dialysis patients):

Recommended starting dose: 2 tablets with each meal.

Dose may be increased gradually to achieve serum phosphate <6 mg/dL, provided hypercalcemia does not occur.

Most patients require 3–4 tablets per meal.

Pediatric Use: Safety and effectiveness not established.

Geriatric Use: No major differences noted in clinical response compared to younger adults, but elderly patients may have greater sensitivity.

✔️ Side Effects

Common: Nausea.

Hypercalcemia (dose-related):

Mild (>10.5 mg/dL): May be asymptomatic or cause constipation, anorexia, nausea, or vomiting.

Severe (>12 mg/dL): May lead to confusion, delirium, stupor, or coma.

Management: Mild cases resolve by reducing or pausing therapy. Severe hypercalcemia may require acute hemodialysis and discontinuation of therapy. Lowering dialysate calcium concentration can reduce risk.

Others: Rare reports of pruritus suggest possible allergic reactions.

✔️ Drug Interactions

May reduce the bioavailability of tetracycline antibiotics.

✔️ Contraindication

Contraindicated in patients with hypercalcemia.

✔️ Pregnancy & Lactation

Category C (Teratogenic risk not ruled out):

No animal reproductive studies available.

Unknown if it causes fetal harm or affects fertility.

Should only be used in pregnancy if clearly necessary.

✔️ Precautions & Warnings

• Monitor serum calcium twice weekly during initiation and dosage adjustments.
• Discontinue or reduce dose if hypercalcemia occurs.
• Avoid use in patients on digitalis, as hypercalcemia may trigger dangerous cardiac arrhythmias.
• Start with the lowest effective dose and increase cautiously with monitoring.
• Educate patients about:
• Strict adherence to prescribed dose
• Following dietary instructions
• Avoiding non-prescription antacids
• Recognizing symptoms of hypercalcemia

✔️ Storage:

Store below 30°C, protected from light and moisture.

Keep out of reach of children.